Neoadjuvant Therapy is Associated with Improved Survival in Borderline-Resectable Pancreatic Cancer.

CONCLUSION: Neoadjuvant therapy is associated with enhanced survival in patients with borderline-resectable pancreatic cancer, which may be attributed to tumor downstaging.
PMID: 31802297 [PubMed - as supplied by publisher]

Source: Ann Oncol - December 3, 2019 Category: Cancer & Oncology Authors: Chawla A, Molina G, Pak LM, Rosenthal M, Mancias JD, Clancy TE, Wolpin BM, Wang J Tags: Ann Surg Oncol Source Type: research